Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $18.66
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Apr 2, 25 | Citizens Capital Markets |
Daily · Wilder smoothing
| maintain |
| Market Outperform |
| Market Outperform |
| Aug 20, 24 | Stifel | maintain | Buy | Buy |
| Jul 26, 24 | JMP Securities | maintain | Market Outperform | Market Outperform |
| Jul 26, 24 | Piper Sandler | maintain | Overweight | Overweight |
| Apr 9, 24 | Stifel | maintain | Buy | Buy |
| Apr 9, 24 | Oppenheimer | maintain | Outperform | Outperform |
| Apr 3, 24 | Piper Sandler | maintain | Overweight | Overweight |
| Nov 6, 23 | Piper Sandler | maintain | Overweight | Overweight |
| Jun 15, 23 | Stifel | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.58 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 22.21 | Oscillator | Neutral |
| Williams %R (14) | -79.11 | Oscillator | Neutral |
| MACD (12, 26, 9) | -2.82 (Hist -0.23) | Oscillator | Strong Sell |
| Average Directional Index (14) | 18.58 (+DI 18.9 / -DI 27.0) | Trend | Neutral |
| EMA 20 | 21.65 | MA | Strong Sell |
| SMA 20 | 21.87 | MA | Strong Sell |
| EMA 50 | 24.88 | MA | Strong Sell |
| SMA 50 | 26.29 | MA | Strong Sell |
| SMA 200 | 20.92 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | CUE | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.7x | -3.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.7x | EPS est. -25.01 | In line |
| Price / Book | 51.2x | 3.0x | Elevated |
| Price / Sales | 3.6x | 27.0x | Discount |
| EV / EBITDA | -1.3x | -2.3x | Discount |
| Return on equity | -1032.2% | — | Weak |
| Gross margin | 99.7% | -36.4% | Below hist. |
| Debt / Equity | 3.81 | 0.31 | Levered |
| Piotroski / Altman Z | 2/9 | Z -30.31 | Distress |
Discounted cash flow model
Stock news · updated daily
Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
Cue Biopharma (NASDAQ: CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluated subcutaneous CUE-221 at doses of 1 mg/kg, 2 mg/kg and 4 mg/kg, administered every four weeks. The trial
I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221's novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food allergy, targeting large market opportunities.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -1.69 | -24.14 | Miss -1328.4% | $7.88M |
| May 14, 2026 | -3.30 | -1.08 | Beat 67.3% | $5.69M |
| Mar 16, 2026 | -2.70 | 0.30 | Beat 111.1% | $21.94M |
| Nov 12, 2025 | -2.80 | -2.10 | Beat 25.0% | $2.15M |
| Aug 12, 2025 | -3.90 | -2.70 | Beat 30.8% | $2.95M |
| May 12, 2025 | -4.20 | -5.11 | Miss -21.7% | $421.0K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 14, 2026 | 2026-10-14 21:39:34 | View |
| 4 | Oct 14, 2026 | 2026-10-14 21:38:15 | View |
| 4 | Oct 14, 2026 | 2026-10-14 21:37:35 | View |
| SC 13G/A | Oct 8, 2026 | 2026-10-08 07:37:06 | View |
| 8-K | Sep 21, 2026 | 2026-09-21 08:00:17 | View |
| 4/A | Aug 28, 2026 | 2026-08-28 17:05:23 | View |
| 4/A | Aug 28, 2026 | 2026-08-28 17:04:26 | View |
| SC 13D | Aug 21, 2026 | 2026-08-21 16:55:01 | View |
| EFFECT | Aug 20, 2026 | 2026-08-21 00:15:18 | View |
| 4 | Aug 17, 2026 | 2026-08-17 18:22:36 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Ray Sumita | officer, other: Chief Legal Compliance Officer | S-Sale | 1,844 @ $28.05 | $51.72K |
| Oct 12, 26 | Meluzio Michael Vincent | officer: VP, Prin. Accounting Officer | S-Sale | 1,144 @ $28.05 | $32.09K |
| Oct 12, 26 | Lin Shao-Lee | director, officer: Chief Executive Officer | S-Sale | 10,000 @ $27.50 | $275.0K |
| Oct 12, 26 | Lin Shao-Lee | director, officer: Chief Executive Officer | S-Sale | 1,087 @ $28.05 | $30.49K |
| Jul 9, 26 | Sarraf Pasha | director | A-Award | 18,400 | — |
| Jul 9, 26 | Garzone Pamela | director | A-Award | 18,900 | — |
| Aug 13, 26 | Ray Sumita | officer, other: Chief Legal Compliance Officer | M-Exempt | 18,196 | — |
| Aug 13, 26 | Ray Sumita | officer, other: Chief Legal Compliance Officer | S-Sale | 2,383 @ $29.37 | $69.99K |